Illumina Inc. (ILMN)

313.83
4.39 1.42
NASDAQ : Health Technology
Prev Close 309.44
Open 309.75
Day Low/High 309.75 / 314.97
52 Wk Low/High 263.30 / 380.76
Volume 619.42K
Avg Volume 1.02M
Exchange NASDAQ
Shares Outstanding 147.00M
Market Cap 45.65B
EPS 5.60
P/E Ratio 49.29
Div & Yield N.A. (N.A)

Latest News

Qiagen Tumbles on Sales Warning, CEO Departure

Qiagen Tumbles on Sales Warning, CEO Departure

Shares of Qiagen slide after the company warns its third-quarter sales will be lower than expected and that its CEO is resigning.

QIAGEN And Illumina Partner To Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

QIAGEN And Illumina Partner To Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.

Illumina And QIAGEN Partner To Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

Illumina And QIAGEN Partner To Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.

Illumina And Broad Institute Announce Agreement To Co-Develop Genomic Secondary Analysis Tools

Illumina And Broad Institute Announce Agreement To Co-Develop Genomic Secondary Analysis Tools

Illumina, Inc. (NASDAQ: ILMN) and the Broad Institute of MIT and Harvard today announced they have entered into a collaboration for the co-development of secondary genomic analysis algorithms and software.

Joydeep Goswami, Illumina Senior Vice President Of Corporate Development And Strategic Planning (Photo: Business Wire)

Joydeep Goswami, Illumina Senior Vice President Of Corporate Development And Strategic Planning (Photo: Business Wire)

Illumina, Inc. (Nasdaq:ILMN) today announced the appointment of Joydeep Goswami as Senior Vice President of Corporate Development and Strategic Planning.

Illumina Recommends Stockholders Reject Mini-Tender Offer By TRC Capital Corporation

Illumina Recommends Stockholders Reject Mini-Tender Offer By TRC Capital Corporation

Illumina, Inc. ("Illumina") (NASDAQ: ILMN) has been notified of an unsolicited "mini-tender offer" by TRC Capital Corporation ("TRC") to purchase up to 500,000 shares of Illumina common stock at a price of $268.

Illumina Reports Financial Results For Second Quarter Of Fiscal Year 2019

Illumina Reports Financial Results For Second Quarter Of Fiscal Year 2019

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2019.

Illumina Expected to Earn $1.34 a Share

Illumina Expected to Earn $1.34 a Share

Illumina revenue expected to rise 3.1% to $855.9 million.

How I Knew to Bet Against Tesla, Netflix and Other Stocks

How I Knew to Bet Against Tesla, Netflix and Other Stocks

Hint: I did my homework and acted when I felt I had the advantage over other market players.

Here's 2 Very Lucrative Trades From My New Trading Venture

Here's 2 Very Lucrative Trades From My New Trading Venture

When stock fundamentals and stock valuations diverge, profit opportunities are created.

When a Good Stock Goes Down: Cramer's 'Mad Money' Recap (Tuesday 7/16/19)

When a Good Stock Goes Down: Cramer's 'Mad Money' Recap (Tuesday 7/16/19)

Jim Cramer says no one ever got hurt taking a profit, but it looks like this is a market worth running to when the stocks of good companies go down.

Illumina Expands Genomics Accelerator To Cambridge, UK

Illumina Expands Genomics Accelerator To Cambridge, UK

Illumina, Inc. (NASDAQ: ILMN) today announced the global expansion of Illumina Accelerator to Cambridge, United Kingdom.

Illumina, One of My Short Stock Candidates, Shows Mediocre Growth

Illumina, One of My Short Stock Candidates, Shows Mediocre Growth

ILMN shares were down about 15% in Friday trading after they pre-announced a revenue miss for its second quarter.

Illumina Plunges on Lower Second-Quarter Guidance

Illumina Plunges on Lower Second-Quarter Guidance

Shares of Illumina plunge on Friday after lowering its second-quarter revenue expectations amid a deferred sale of at least one its gene-sequencing machine systems.

Illumina Reports Preliminary Revenue For Second Quarter Of Fiscal Year 2019

Illumina Reports Preliminary Revenue For Second Quarter Of Fiscal Year 2019

Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance.

Coming Up Short? Here Are Some Stocks to Consider

Coming Up Short? Here Are Some Stocks to Consider

To effectively generate profits, a trader must pick several companies in a sector and short the whole bunch.

As 'Precision Medicine' Starts to Take Off, Here's Who's Poised to Capitalize

As 'Precision Medicine' Starts to Take Off, Here's Who's Poised to Capitalize

Precision medicine is like a smart bomb that bases treatment on a patient's individual genetics. One company makes the hardware and software to help make it happen.

Illumina Files Patent Infringement Suits Related To BGI In Switzerland, Turkey And The US

Illumina Files Patent Infringement Suits Related To BGI In Switzerland, Turkey And The US

Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed three additional patent infringement suits relating to BGI's sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents.

Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal

Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal

Initial inquiry into deal showed it could remove what might be most significant competitive threat to Illumina.

Illumina Wins Infringement Suit Against Ariosa Diagnostics, Inc.

Illumina Wins Infringement Suit Against Ariosa Diagnostics, Inc.

Illumina, Inc. (NASDAQ: ILMN) announced today that the High Court of Justice, Chancery Division, Patents Court in the United Kingdom issued a judgment in its favor in the patent infringement suit filed against Ariosa Diagnostics, Inc.

VeriSeq NIPT Solution V2 (Photo: Business Wire)

VeriSeq NIPT Solution V2 (Photo: Business Wire)

Illumina, Inc. (NASDAQ: ILMN) today announced the launch of VeriSeq ™ NIPT Solution v2, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT).

Illumina To Webcast Upcoming Investor Conference Presentation

Illumina To Webcast Upcoming Investor Conference Presentation

Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.

Illumina Files Patent Infringement Suit Against BGI In Denmark

Illumina Files Patent Infringement Suit Against BGI In Denmark

Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed another patent infringement suit against one of BGI Group's subsidiaries, BGI Europe A/S.

Population Health Study Goes Statewide As University Medical Center Of Southern Nevada Serves As Host Site For Enrollment Of 25,000 More Nevadans

Population Health Study Goes Statewide As University Medical Center Of Southern Nevada Serves As Host Site For Enrollment Of 25,000 More Nevadans

The study could expand to a quarter million people, making Nevada the only state in the U.S. to offer such a program

Illumina To Webcast Upcoming Investor Conference Presentation

Illumina To Webcast Upcoming Investor Conference Presentation

Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.

Helix Expands Focus To Population Health Solutions And Appoints Illumina Veteran Marc Stapley As CEO

Helix Expands Focus To Population Health Solutions And Appoints Illumina Veteran Marc Stapley As CEO

SAN CARLOS, Calif., April 25, 2019 /PRNewswire/ -- Helix today announced it is broadening its market focus to include health systems, payers and researchers who are interested in sequencing large population cohorts.

Illumina Reports Financial Results For First Quarter Of Fiscal Year 2019

Illumina Reports Financial Results For First Quarter Of Fiscal Year 2019

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2019.

The New #37 Most Shorted Nasdaq 100 Component: Illumina

The New #37 Most Shorted Nasdaq 100 Component: Illumina

The most recent short interest data has been released for the 03/29/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

TheStreet Quant Rating: B (Buy)